Macquarie Group LTD Pro Qr Therapeutics N.V. Call Options Transaction History
Macquarie Group LTD
- $87.4 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding PRQR
# of Institutions
52Shares Held
17.4MCall Options Held
52.5KPut Options Held
11.8K-
Privium Fund Management B.V.5.34MShares$8.87 Million3.62% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.63MShares$6.02 Million0.02% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA2.88MShares$4.79 Million0.19% of portfolio
-
M28 Capital Management LP Stamford, CT1.02MShares$1.69 Million2.19% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA906KShares$1.5 Million0.5% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $118M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...